S A Gayther

Summary

Affiliation: University of Cambridge
Country: UK

Publications

  1. ncbi The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes
    S A Gayther
    Department of Oncology, Cancer Research Campaign, Strangeways Research Laboratory, Cambridge, United Kingdom
    Am J Hum Genet 65:1021-9. 1999
  2. ncbi The genetics of inherited breast cancer
    S A Gayther
    CRC Human Cancer Genetics Research Group, Addenbrooke s Hospital, Cambridge, United Kingdom
    J Mammary Gland Biol Neoplasia 3:365-76. 1998
  3. ncbi Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers
    P A Russell
    CRC Department of Oncology, Strangeways Research Laboratory, Cambridge, UK
    Int J Cancer 87:317-21. 2000
  4. ncbi Risk models for familial ovarian and breast cancer
    A C Antoniou
    CRC Genetic Epidemiology Unit, Institute of Public Health, University of Cambridge, Cambridge, United Kingdom
    Genet Epidemiol 18:173-90. 2000
  5. ncbi Mutations truncating the EP300 acetylase in human cancers
    S A Gayther
    Department of Oncology, University of Cambridge, Cambridge, UK
    Nat Genet 24:300-3. 2000
  6. ncbi Apparent human BRCA1 knockout caused by mispriming during polymerase chain reaction: implications for genetic testing
    B Kuschel
    CRC Human Cancer Genetics Research Group, Department of Oncology, Strangeways Research Laboratories, Cambridge, England
    Genes Chromosomes Cancer 31:96-8. 2001
  7. ncbi A gene (DLG2) located at 17q12-q21 encodes a new homologue of the Drosophila tumor suppressor dIg-A
    S Mazoyer
    CRC Human Cancer Genetics Research Group, Addenbrooke s Hospital, Cambridge, United Kingdom
    Genomics 28:25-31. 1995
  8. ncbi Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours
    S A Gayther
    CRC Human Cancer Genetics Research Group, Addenbrooke s Hospital, Cambridge, UK
    Oncogene 15:2119-26. 1997
  9. ncbi Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia
    S A Gayther
    Am J Hum Genet 60:1239-42. 1997
  10. ncbi Identification of germ-line E-cadherin mutations in gastric cancer families of European origin
    S A Gayther
    Department of Oncology and Cancer Research Campaign Human Cancer Genetics Research Group, University of Cambridge, Addenbrooke s Hospital, United Kingdom
    Cancer Res 58:4086-9. 1998

Collaborators

Detail Information

Publications15

  1. ncbi The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes
    S A Gayther
    Department of Oncology, Cancer Research Campaign, Strangeways Research Laboratory, Cambridge, United Kingdom
    Am J Hum Genet 65:1021-9. 1999
    ..We discuss the implications for genetic testing and clinical management of familial ovarian cancer arising from the data presented in these studies...
  2. ncbi The genetics of inherited breast cancer
    S A Gayther
    CRC Human Cancer Genetics Research Group, Addenbrooke s Hospital, Cambridge, United Kingdom
    J Mammary Gland Biol Neoplasia 3:365-76. 1998
    ..We review the evidence for gene-gene and gene-environment interaction in modifying that risk, and discuss the contribution of BRCA1 and BRCA2 and other high penetrance genes to both inherited and sporadic breast cancer...
  3. ncbi Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers
    P A Russell
    CRC Department of Oncology, Strangeways Research Laboratory, Cambridge, UK
    Int J Cancer 87:317-21. 2000
    ..Together, these data suggest that expression of BRCA1 is down-regulated at the level of transcription during the development of sporadic ovarian cancers...
  4. ncbi Risk models for familial ovarian and breast cancer
    A C Antoniou
    CRC Genetic Epidemiology Unit, Institute of Public Health, University of Cambridge, Cambridge, United Kingdom
    Genet Epidemiol 18:173-90. 2000
    ..The high penetrance estimate for ovarian cancer, compared with other studies, suggests that modifying genetic or environmental factors may be important determinants of risk...
  5. ncbi Mutations truncating the EP300 acetylase in human cancers
    S A Gayther
    Department of Oncology, University of Cambridge, Cambridge, UK
    Nat Genet 24:300-3. 2000
    ..Our data show that EP300 is mutated in epithelial cancers and provide the first evidence that it behaves as a classical tumour-suppressor gene...
  6. ncbi Apparent human BRCA1 knockout caused by mispriming during polymerase chain reaction: implications for genetic testing
    B Kuschel
    CRC Human Cancer Genetics Research Group, Department of Oncology, Strangeways Research Laboratories, Cambridge, England
    Genes Chromosomes Cancer 31:96-8. 2001
    ..This may have major implications for the sensitivity of all polymerase chain reaction-based mutation-detection methods in clinical genetic testing laboratories...
  7. ncbi A gene (DLG2) located at 17q12-q21 encodes a new homologue of the Drosophila tumor suppressor dIg-A
    S Mazoyer
    CRC Human Cancer Genetics Research Group, Addenbrooke s Hospital, Cambridge, United Kingdom
    Genomics 28:25-31. 1995
    ..No evidence for mutation was found, making it unlikely that DLG2 is involved in sporadic breast cancer...
  8. ncbi Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours
    S A Gayther
    CRC Human Cancer Genetics Research Group, Addenbrooke s Hospital, Cambridge, UK
    Oncogene 15:2119-26. 1997
    ..While we cannot exclude that alterations in TSG101 and FHIT occur during cancer development, our data indicate that in this context the commonly observed transcript abnormalities are misleading...
  9. ncbi Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia
    S A Gayther
    Am J Hum Genet 60:1239-42. 1997
  10. ncbi Identification of germ-line E-cadherin mutations in gastric cancer families of European origin
    S A Gayther
    Department of Oncology and Cancer Research Campaign Human Cancer Genetics Research Group, University of Cambridge, Addenbrooke s Hospital, United Kingdom
    Cancer Res 58:4086-9. 1998
    ..Here, we show that a proportion of diffuse gastric cancer families of European origin have germ-line E-cadherin mutations; however, these mutations are absent in intestinal gastric cancer families...
  11. ncbi Somatic mitochondrial DNA mutations in primary and metastatic ovarian cancer
    P O Van Trappen
    Gynaecological Cancer Centre and Centre for Translational Oncology, Institute of Cancer and CR UK Clinical Centre, Barts and The London, Queen Mary s School of Medicine and Dentistry, John Vane Science Centre, London, UK
    Gynecol Oncol 104:129-33. 2007
    ..To establish whether different mtDNA variants can be found in the same cancer but at different sites, we analyzed a series of unilateral and bilateral primary epithelial ovarian cancers as well as paired metastatic tumor deposits...
  12. ncbi Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours
    L Khalique
    Translational Research Laboratory, Department of Gynaecological Oncology, Institute for Women s Health, University College London, UK
    J Pathol 211:286-95. 2007
    ..The basis of genetic ITH and the possible implications for molecular approaches to clinical diagnosis of ovarian cancers may apply to other tumour types...
  13. ncbi Human ovarian surface epithelial cells immortalized with hTERT maintain functional pRb and p53 expression
    N F Li
    Centre for Translational Oncology, Barts and The London, Queen Mary s School of Medicine and Dentistry, Charterhouse Square, London, UK
    Cell Prolif 40:780-94. 2007
    ..Establishment of immortalized OSE cell lines has, in the past, required inactivation of pRb and p53 functions. However, this often leads to increased chromosome instability during prolonged culture...
  14. ncbi Grading of serous ovarian carcinoma: further evidence of a lack of agreement between conventional grading systems
    N Singh
    Histopathology 52:393-5. 2008
  15. ncbi Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis
    C L Pearce
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90089, USA
    Br J Cancer 98:282-8. 2008
    ..80, 95% CI 0.62-1.04, P=0.100). These data suggest that while these three variants in the PGR are not associated with ovarian cancer overall, the PROGINS variant may play a modest role in risk of endometrioid ovarian cancer...